Publication


Featured researches published by Michelle Ann Tscheiner.


Peptides | 2005

Sauvagine analogs selective for corticotropin releasing factor 2 receptor: effect of substitutions at positions 35 and 39 on CRF2R selectivity

Adam W. Mazur; Feng Wang; Michelle Ann Tscheiner; Elizabeth Donnelly; Robert J. Isfort

Corticotropin releasing factor 2 receptor selective analogs of the amphibian peptide sauvagine, a member of the corticotropin releasing factor (CRF) peptide family, have therapeutic potential for the treatment of skeletal muscle atrophy. Previously, we demonstrated that [P11X12X13]Svg peptides have improved CRF2R selectivity, although not to the level of CRF2R selective hormones such as urocortin 2 and urocortin 3. Since we also demonstrated a potential for improvement in selectivity of sauvagine by modifications of residues 35 and 39, we investigated substitutions of these amino acids in selected [P11X12X13]Svg peptides. We have observed that substitution of Arg35 in sauvagine to Ala35 (the amino acid found in all CRF2R selective agonists), increased the selectivity of [P11, X12, X13]Svg analogs. In contrast, substitution of Asp39 in sauvagine to Ala39 (also the amino acid found in all CRF2R selective agonists) did not further increase the selectivity of [P11, X12, X13, A35]Svg analogs. Thus, the residues 35 along with 11, 12, and 13 in sauvagine represent important sites for improving CRF2R selectivity.


Peptides | 2006

Modifications of the human urocortin 2 peptide that improve pharmacological properties.

Robert J. Isfort; Feng Wang; Michelle Ann Tscheiner; Elizabeth Dolan; Mary Beth Bauer; F.R. Lefever; Deborah L Reichart; Kenneth R. Wehmeyer; Raymond A. Reilman; Bradly D. Keck; Richard T. Hinkle; Adam W. Mazur

Recently, we demonstrated that the corticotropin releasing factor 2 receptor agonist, urocortin 2, demonstrated anti-atrophy effects in rodent skeletal muscle atrophy models. Compared to other CRF2R agonists however, the in vivo pharmacological potency of urocortin 2 is poor when it is administered by continuous subcutaneous infusion. Therefore, we attempted to modify the structure of urocortin 2 to improve in vivo efficacy when administered by subcutaneous infusion. By substituting amino acid residues in the linker region of urocortin 2 (residues 22-32), we have demonstrated improved in vivo potency without altering selectivity, probably through reduced CRFBP binding. In addition, attempts to shorten urocortin 2 generally resulted in inactive peptides, demonstrating that the 38 amino acid urocortin 2 peptide is the minimal pharmacophore.


Journal of Medicinal Chemistry | 2005

Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy.

Robert J. Isfort; Feng Wang; Michelle Ann Tscheiner; Elizabeth Donnelly; Mary Beth Bauer; F.R. Lefever; Richard T. Hinkle; Adam W. Mazur


Journal of Medicinal Chemistry | 2004

Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides

Adam W. Mazur; Feng Wang; Michelle Ann Tscheiner; Elizabeth Donnelly; Robert J. Isfort


Archive | 2012

Surface treatment compositions including poly(diallyldimethylammonium chloride) and sheilding salts

Sherri Lynn Randall; Michelle Ann Tscheiner; Eric Scott Johnson; Mark Robert Sivik


Archive | 2012

Surface treatment compositions including polyquaternium-22 and sheilding salts

Sherri Lynn Randall; Michelle Ann Tscheiner; Eric Scott Johnson; Mark Robert Sivik


Archive | 2012

Surface treatment compositions including shielding salts

Sherri Lynn Randall; Michelle Ann Tscheiner; Eric Scott Johnson; Mark Robert Sivik


Archive | 2017

composições para tratamento de superfícies incluindo sais protetores

Eric Scott Johnson; Mark Robert Sivik; Michelle Ann Tscheiner; Sherri Lynn Randall


Archive | 2017

composições para tratamento de superfícies que incluem sais protetores

Eric Scott Johnson; Mark Robert Sivik; Michelle Ann Tscheiner; Sherri Lynn Randall


Archive | 2014

COMPOSICIONES PARA TRATAR SUPERFICIES INCLUYENDO SALES PROTECTORAS

Sherri Lynn Randall; Michelle Ann Tscheiner; Eric Scott Johnson; Mark Robert Sivik

Researchain Logo
Decentralizing Knowledge